Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scoring tool aims to reverse type 2 diabetes with personalized plans

NCT ID NCT07606872

Disease control Sponsor: Salah Snouda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each patient. 150 adults will follow a personalized 24-week lifestyle and nutrition plan based on their SMS results. The goal is to see if this tailored approach improves blood sugar control and can lead to diabetes remission (HbA1c below 6.5% without medication). The study is done entirely online through a digital platform.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider * Age 18 years or older * HbA1c between 6.5% and 11.0% at baseline * Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas) * Ability to access and use the diabetesreversal.io digital platform * Willingness to perform daily self-monitoring of blood glucose * Willingness to complete laboratory blood tests (Genesis Biomarker Panel) at baseline and Week 24 at own expense * Able to provide written informed consent Exclusion Criteria: * Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA) * Currently pregnant or breastfeeding * Currently using insulin therapy * Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide) * HbA1c greater than 11.0% at baseline * History of severe hypoglycemia requiring third-party assistance in the past 12 months * Active malignancy or receiving chemotherapy or radiation therapy * Severe renal impairment (eGFR less than 30 mL/min/1.73m²) * Severe hepatic impairment * Active eating disorder * Any condition that in the opinion of the investigator would make participation unsafe or interfere with study completion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome inborn mitochondrial metabolism disorder Insulin Resistance Intermittent Fasting metabolic syndrome X type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Metabolic syndrome Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Snouda Health Coaching Ltd

    Manchester, England, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.